PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Zeng, Jian
Wang, Guoqiang
Yan, Zhengqing
Zheng, Hao
Li, Jianqiang
Tao, Feng
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Surg, Hangzhou, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China
[3] Wen Zhou Med Univ, Lishui Peoples Hosp, Dept Resp Med, Affiliated Hosp 6, Lishui, Peoples R China
[4] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[5] Jiaxing Univ, Dept Resp Med, Affiliated Hosp, Jiaxing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15112
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    CANCER, 2018, 124 (02) : 248 - 261
  • [22] Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Boumber, Yanis
    Borghaei, Hossein
    CANCER, 2020, 126 (02) : 260 - 270
  • [23] Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer
    Lee, J. C.
    Choi, M. G.
    Ji, W.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S357 - S358
  • [24] The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations
    Sakamoto, Hiroaki
    Tanaka, Hisashi
    Shiratori, Toshihiro
    Baba, Keisuke
    Ishioka, Yoshiko
    Itoga, Masamichi
    Taima, Kageaki
    Hasegawa, Yukihiro
    Takanashi, Shingo
    Tasaka, Sadatomo
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (06) : 610 - 614
  • [25] Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
    Wang, Haowei
    Cheng, Lei
    Zhao, Chao
    Zhou, Fei
    Jiang, Tao
    Guo, Haoyue
    Shi, Jinpeng
    Chen, Peixin
    Tang, Zhuoran
    Mao, Shiqi
    Jia, Keyi
    Ye, Lingyun
    Cai, Chenlei
    Li, Xuefei
    Chen, Xiaoxia
    Zhou, Caicun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 219 - +
  • [26] Small Cell Transformation of Non-Small Cell Lung Cancer (NSCLC) on Immune Checkpoint Inhibitors: Case Report and Literature Review
    Sehgal, K.
    Varkaris, A.
    Vanderlaan, P.
    Rangachari, D.
    Costa, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S470 - S471
  • [27] Clinical Responses to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Patient Characteristics and Predictors
    Mittal, Garima
    Salas, Maribel
    Ghazarian, Armen
    Malhotra, Jyoti
    Bates, Benjamin
    Chen, Wenjin
    Setoguchi, Soko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 168 - 168
  • [28] Role of Immune Checkpoint Inhibitors (ICPi) in KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Peravali, M.
    Gomes-Lima, C.
    Tefera, E.
    Baker, M.
    Sherchan, M.
    Farid, S.
    Burman, K.
    Constantinescu, F.
    Veytsman, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S300 - S301
  • [29] Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC)
    Lahmar, J.
    Mezquita, L.
    Koscielny, S.
    Facchinetti, F.
    Bluthgen, M. V.
    Adam, J.
    Gazzah, A.
    Remon, J.
    Planchard, D.
    Soria, J-C.
    Caramella, C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1).
    Iranzo, Patricia
    Callejo, Ana
    Pedrola, Anna
    Pardo Aranda, Nuria
    Navarro, Alejandro
    Martinez-Marti, Alex
    Cedres Perez, Susana
    Ros, Javier
    David Assaf, Juan
    Saoudi, Nadia
    Carbonell, Caterina
    Amat, Ramon
    Frigola, Joan
    Jimenez, Jose
    Dienstmann, Rodrigo
    Palmer, Hector G.
    Vivancos, Ana
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345